产品批准和商业化 - X4获得XOLREMDI(mavorixafor)在WHIM综合征12岁及以上患者中的FDA批准[6] - X4正在执行XOLREMDI在美国的上市,包括与目标医生和罕见疾病患者倡导组织增加互动,持续开展疾病宣传和教育活动,以及启动X4Connect和护士教育项目提供患者支持服务[6,7] - X4计划于2025年初向欧洲药品管理局(EMA)提交mavorixafor用于WHIM综合征的监管申请,并正在探索其他可能的地理区域机会[7] 临床试验进展 - X4在慢性中性粒细胞减少症(CN)的II期临床试验中获得积极的中期数据,显示每日口服mavorixafor作为单药或与G-CSF联合使用能够持续增加参与者的绝对中性粒细胞计数(ANC)[8] - X4启动了针对CN患者的III期4WARD临床试验,旨在评估口服每日mavorixafor(单药或联合G-CSF)的疗效、安全性和耐受性[8] 财务表现 - X4在2024年第二季度实现了0.6百万美元的XOLREMDI产品销售收入,成本为0.3百万美元,其中包括0.2百万美元的许可费用[9] - X4在2024年第二季度实现了9,080万美元的净利润,主要包括1.05亿美元的优先审评券出售收益和2,020万美元的衍生工具公允价值变动收益[10] - X4在2024年6月30日拥有1.695亿美元的现金、现金等价物、受限现金和短期有价证券,预计可支持公司运营至2025年底[9] - X4在2024年第二季度的研发费用为2,090万美元,销售及管理费用为1,330万美元[10] - 公司在2024年上半年实现产品收入563,000美元[20] - 公司在2024年上半年的研发费用为20,914,000美元[20] - 公司在2024年上半年的销售、一般及管理费用为13,278,000美元[20] - 公司在2024年上半年实现了105,000,000美元的非金融资产出售收益[20] - 公司在2024年上半年实现净利润90,833,000美元[20] - 公司在2024年6月30日的现金及现金等价物为147,218,000美元[21] - 公司在2024年6月30日的总资产为210,611,000美元[21] - 公司在2024年6月30日的总负债为116,160,000美元[21] - 公司在2024年6月30日的总股东权益为94,451,000美元[21] - 公司在2024年上半年的每股基本收益为0.45美元[20]

Dr_Microbe One of my favorite duties as the leader of our Seeking Alpha Investing Group is answering questions from members and providing analysis of their prospective trades or tickers. Recently, one of the members inquired about X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) and why the ticker was selling off following they publicized mixed interim data from mavorixafor’s Phase II study for chronic neutropenia (CN). The data revealed that 3 out of 23 patients on Mavorixafor discontinued due to non-serious adv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

X4 Pharmaceuticals Inc (NASDAQ:XFOR) Q1 2024 Results Conference Call May 7, 2024 8:30 AM ET Company Participants Dan Ferry - IR Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - COO Mark Baldry - CMO Conference Call Participants Stephen Willey - Stifel Edward Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright David Bautz - Zacks Small Cap Research Operator [Indiscernible] X4 Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this ti ...

Exhibit 99.1 X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial in chronic neutropenia expected at a planned company investor event in June 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38295 _________________________________________________________________________________________________________ X4 PHARMACEUTICALS, INC. ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dr. Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Mark Baldry - Chief Commercial Officer Dr. Christophe Arbet-Engels - Chief Medical Officer Mary DiBiase - Chief Operating Officer Art Taveras - Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Ed Tenthoff - Piper Sandler Sean Lee - H.C. Wa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer Christophe Arbet-Engels – Chief Medical Officer Adam Mostafa – Chief Financial Officer Conference Call Participants Eva Privitera – TD Cowen Stephen Willey – Stifel Edward Tenthoff – Piper Sandler Andy Fleszar – B. Riley Securities Kristen Kluska – Cantor Fitzgerald Swayampakula Rama ...

November 9, 2023 | --- | --- | --- | --- | --- | --- | |--------------------------------------------------|----------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | PROGRESS | PATIENTS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Developing the first oral treatments for chronic | | | | | | | | | | | | | | neutropenic disorders | | | | | | | | | ...